Postmarketing study of ORTHO EVRA® and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism

Contraception ◽  
2010 ◽  
Vol 81 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Susan S. Jick ◽  
Katrina W. Hagberg ◽  
Rohini K. Hernandez ◽  
James A. Kaye
Keyword(s):  
Venous Thromboembolism ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Hormonal Contraceptives

scholarly journals Portal Venous Thrombosis Associated with Use of Etonogestrel/ethinyl Estradiol Vaginal Ring

2020 ◽  
Vol 4 (2) ◽  
pp. 263-266
Author(s):  
Katelynn Bailey ◽  
Michael Tranovich
Keyword(s):  
Abdominal Pain ◽  
Venous Thrombosis ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Vaginal Ring ◽  
Hormonal Contraceptives ◽  
Term Outcome ◽  
Life Threatening ◽  
Portal Venous Thrombosis

Introduction: Portal venous thrombosis is a life-threatening cause of abdominal pain. In younger patients, heritable thrombophilias, pregnancy, tobacco use, and oral contraceptives are associated. Case Report: A 26-year-old woman prescribed contraceptive vaginal ring presented with abdominal pain and was diagnosed with an extensive portal venous thrombosis. Management included heparin and later an oral anticoagulant with good short-term outcome. Discussion: Women using hormonal contraception are approximately four times more likely to develop thromboembolism. Risk of thromboembolism is similar between users of intravaginal and oral contraceptives. Conclusion: Portal venous thrombosis must be considered in women presenting with abdominal pain who are prescribed hormonal contraceptives, including intravaginal forms.

scholarly journals MECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism

2014 ◽  
Vol 171 (6) ◽  
pp. R221-R230 ◽  
Author(s):  
Justine Hugon-Rodin ◽  
Anne Gompel ◽  
Geneviève Plu-Bureau
Keyword(s):  
Venous Thromboembolism ◽  
Second Generation ◽  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Current Data ◽  
Biological Data ◽  
Sex Hormone Binding Globulin ◽  
Hormonal Contraceptives ◽  
Low Doses ◽  
Thrombotic Risk

For many years, it has been well documented that combined hormonal contraceptives increase the risk of venous thromboembolism (VTE). The third-generation pill use (desogestrel or gestodene (GSD)) is associated with an increased VTE risk as compared with second-generation (levonorgestrel) pill use. Other progestins such as drospirenone or cyproterone acetate combined with ethinyl-estradiol (EE) have been investigated. Most studies have reported a significant increased VTE risk among users of these combined oral contraceptives (COCs) when compared with users of second-generation pills. Non-oral combined hormonal contraception, such as the transdermal patch and the vaginal ring, is also available. Current data support that these routes of administration are more thrombogenic than second-generation pills. These results are consistent with the biological evidence of coagulation activation. Overall, the estrogenic potency of each hormonal contraceptive depending on both EE doses and progestin molecule explains the level of thrombotic risk. Some studies have shown a similar increased VTE risk among users of COCs containing norgestimate (NGM) as compared with users of second-generation pill. However, for this combination, biological data, based on quantitative assessment of sex hormone-binding globulin or haemostasis parameters, are not in agreement with these epidemiological results. Similarly, the VTE risk associated with low doses of EE and GSD is not biologically plausible. In conclusion, newer generation formulations of hormonal contraceptives as well as non-oral hormonal contraceptives seem to be more thrombogenic than second-generation hormonal contraceptives. Further studies are needed to conclude on the combinations containing NGM or low doses of EE associated with GSD.

Decreased Levels of Histidine-Rich Glycoprotein (HRG) and Increased Levels of Free Plasminogen in Women on Oral Contraceptives Low in Estrogen

1982 ◽  
Vol 48 (03) ◽  
pp. 283-285 ◽  
Author(s):  
Jørgen Jespersen ◽  
Cornelis Kluft
Keyword(s):  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Relative Increase ◽  
Normal Group ◽  
Plasma Samples ◽  
Normal Women ◽  
Made In

SummaryDeterminations by immunologic methods of histidine-rich glycoprotein (HRG) and plasminogen, were made in plasma samples collected during one normal or hormone induced cycle in 15 young, normal women and in 11 women using oral contraceptives with 30 μg ethinyl estradiol and 150 μg levo-norgestrel. The hormone group showed an increase in plasminogen level to about 150% of normal, while the concentration of HRG was decreased to about 75% of normal. This resulted in a considerable relative increase in the concentration of free plasminogen in the hormone group (calculated from the equilibrium: HRG·plasminogen ⇌ HRG + plasminogen, using KD = 1.0 μM), representing a doubling of that in the normal group. Hence, more plasminogen is available for binding to fibrin and activation in the hormone group.

Hormonal contraception as a method of social adaptation of women in modern society

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (3) ◽  
pp. 17-21
Author(s):  
Tatyana Yu Pestrikova ◽  
Elena A Yurasova ◽  
Igor V Yurasov ◽  
Tamara D Kovaleva
Keyword(s):  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Modern Society ◽  
Well Being ◽  
Social Adaptation ◽  
Female Employment ◽  
Hormonal Contraceptives ◽  
Aim Analysis ◽  
Positive Effects ◽  
Chlormadinone Acetate

Relevance. Currently, women make up more than 40% of the global workforce and more than half of students studying at universities around the world. Women's education, especially at a high level, tends to increase female employment. The mismatch of the style and rhythm of modern life with a genetically determined and working millennium reproductive program requires the choice of a specific approach to social adaptation. Aim. Analysis of literary sources on the use of hormonal contraception as a method of social adaptation. Materials and methods. To write this review, domestic and foreign publications were searched in Russian and international search systems (PubMed, eLibrary, etc.) for the last 2-10 years. The review included articles from peer-reviewed literature. Results. The review describes the features of modern hormonal contraceptives. Their non-contraceptive effects are presented. The individual non-contraceptive effects of a combined oral contraceptive containing 30 mg of ethinyl estradiol and 2 mg of chlormadinone acetate were determined. It has been established that the use of this contraceptive helps to improve the well-being and mood of patients, which allows you to actively use this contraceptive in routine clinical practice with premenstrual syndrome, dysmenorrhea, without the use of analgesics. Conclusions. The numerous positive effects of ethinyl estradiol and chlormadinone acetate allow the use of the drug as a means to increase social adaptation, and, consequently, improve the quality of life.

Sign in / Sign up

Export Citation Format

Share Document